JAK inhibitors are used to treat myelofibrosis.

Published Date: 12 Sep 2023

Although "in the frontline proliferative setting, ruxolitinib has remained the standard of care," "we are thankfully starting to be blessed with more options than we've ever had.". ".

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: When will individuals be able to receive customized cancer vaccines?

2.

Canadian Group Calls for Earlier Colorectal Cancer Screening

3.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

4.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

5.

Talquetamab Combos Show Survival Benefit in r/r Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot